These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38442535)

  • 1. Experience of patients on methadone maintenance treatment receiving take-home methadone doses during COVID-19 pandemic: A multi-site study from India.
    Kathiresan P; Patel V; Jangra J; Chattopadhyay A; Abdus S; Jadhav M; Rao R; Arya A; Bansal PD; Chinggouman C; Bhad R; Ambekar A; Agrawal A; Chatterjee B; Yadav D
    Asian J Psychiatr; 2024 May; 95():103979. PubMed ID: 38442535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
    Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
    JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.
    Dunn KE; Brooner RK; Stoller KB
    J Subst Abuse Treat; 2021 Feb; 121():108197. PubMed ID: 33357606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19.
    Figgatt MC; Salazar Z; Day E; Vincent L; Dasgupta N
    J Subst Abuse Treat; 2021 Apr; 123():108276. PubMed ID: 33612201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis.
    Kitchen SA; Campbell TJ; Men S; Bozinoff N; Tadrous M; Antoniou T; Wyman J; Werb D; Munro C; Gomes T
    Int J Drug Policy; 2022 May; 103():103644. PubMed ID: 35272107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
    Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
    Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
    [No Abstract]   [Full Text] [Related]  

  • 7. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
    Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
    Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
    Brothers S; Viera A; Heimer R
    J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
    Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
    J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: Should this practice be incorporated into routine clinical care?
    Trujols J; Larrabeiti A; Sànchez O; Madrid M; De Andrés S; Duran-Sindreu S
    J Subst Abuse Treat; 2020 Dec; 119():108154. PubMed ID: 33032860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
    Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
    Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
    [No Abstract]   [Full Text] [Related]  

  • 12. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
    Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
    J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids.
    Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19-related flexibility in methadone take-home doses associated with decreased attrition: Report from an opioid treatment program in central Pennsylvania.
    Kawasaki SS; Zimmerman R; Shen C; Zgierska AE
    J Subst Use Addict Treat; 2023 Dec; 155():209164. PubMed ID: 37730014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "It didn't hurt me": patients' and providers' perspectives on unsupervised take-home doses, drug diversion, and overdose risks in the provision of medication for opioid use disorder during COVID-19 in San Juan, Puerto Rico.
    Abadie R; Fisher CB
    Harm Reduct J; 2024 Apr; 21(1):85. PubMed ID: 38664796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
    Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
    Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
    Wu LT; John WS; Morse ED; Adkins S; Pippin J; Brooner RK; Schwartz RP
    Addiction; 2022 Feb; 117(2):444-456. PubMed ID: 34286886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot investigation of an electronic pillbox at a community opioid treatment program.
    Sklar M; Doyle S; Kidorf M
    Am J Drug Alcohol Abuse; 2024 May; 50(3):328-333. PubMed ID: 38557232
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in methadone take-home dosing before and after COVID-19.
    Amram O; Amiri S; Thorn EL; Lutz R; Joudrey PJ
    J Subst Abuse Treat; 2022 Feb; 133():108552. PubMed ID: 34304950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance.
    Gerra G; Saenz E; Busse A; Maremmani I; Ciccocioppo R; Zaimovic A; Gerra ML; Amore M; Manfredini M; Donnini C; Somaini L
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):483-9. PubMed ID: 21147192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.